Evaluating measurable residual disease in acute myeloid leukemia
Farhad Ravandi1, Roland B Walter2,3, Sylvie D Freeman4
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract:
Mounting evidence indicates that the presence of measurable ("minimal") residual disease (MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic detection, is a strong, independent prognostic marker of increased risk of relapse and shorter survival in patients with acute myeloid leukemia (AML) and can be used to refine risk-stratification and treatment response assessment. Because of the association between MRD and relapse risk, it has been postulated that testing for MRD posttreatment may help guide postremission treatment strategies by identifying high-risk patients who might benefit from preemptive treatment. This strategy, which remains to be formally tested, may be particularly attractive with availability of agents that could be used to specifically eradicate MRD. This review examines current methods of MRD detection, challenges to adopting MRD testing in routine clinical practice, and recent recommendations for MRD testing in AML issued by the European LeukemiaNet MRD Working Party. Inclusion of MRD as an end point in future randomized clinical trials will provide the data needed to move toward standardizing MRD assays and may provide a more accurate assessment of therapeutic efficacy than current morphologic measures.
Insights
Minimal residual disease (MRD) detection in acute myeloid leukemia (AML) is a key prognostic marker. Post-treatment MRD testing can guide therapy and improve patient outcomes by identifying high-risk individuals.
Area of Science:
- Hematology
- Oncology
- Clinical Pathology
Background:
- Measurable residual disease (MRD) is a significant prognostic indicator in acute myeloid leukemia (AML).
- Persistence of leukemic cells below morphologic detection levels correlates with increased relapse risk and reduced survival.
- MRD assessment refines risk-stratification and treatment response evaluation in AML patients.
Purpose of the Study:
- To review current methods for detecting MRD in AML.
- To discuss challenges in implementing routine MRD testing in clinical practice.
- To present recent European LeukemiaNet MRD Working Party recommendations for MRD testing in AML.
Main Methods:
- Review of existing literature on MRD detection techniques in AML.
- Analysis of challenges and barriers to routine clinical adoption of MRD assays.
- Examination of European LeukemiaNet MRD Working Party guidelines.
Main Results:
- MRD is a strong predictor of relapse and survival in AML.
- Post-treatment MRD testing may guide preemptive treatment strategies for high-risk patients.
- Standardization of MRD assays is needed, with clinical trials crucial for validation.
Conclusions:
- MRD is an essential prognostic marker in AML, impacting treatment decisions.
- Further research and standardization are required to integrate MRD testing into routine clinical practice.
- MRD assessment offers a more accurate measure of therapeutic efficacy compared to morphologic assessments.
More Related Videos
Related Concept Videos
Residual Plots
When the residual values are plotted against the variable x, it is called a residual...
Residual Stresses
Residual Stresses in Circular Shafts
Residual Stresses in Bending
Residuals and Least-Squares Property
If the observed data point lies above the line, the residual is positive, and the line underestimates the actual data value for y. If the observed data point lies below the line, the residual is negative, and the line overestimates the actual data value for y.
The process of fitting the best-fit...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation


